R P Finger

Summary

Affiliation: University of Bonn
Country: Germany

Publications

  1. ncbi [Blindness in Germany: dimensions and perspectives]
    R P Finger
    Universitätsaugenklinik Bonn, Ernst Abbe Strasse 2, 53127, Bonn
    Ophthalmologe 104:839-44. 2007
  2. ncbi [Trends in inpatient treatment in ophthalmology in Germany]
    R P Finger
    Universitätsaugenklinik Bonn, Ernst Abbe Str 2, 53127, Bonn, Deutschland
    Ophthalmologe 110:224-9. 2013
  3. ncbi Blindness and visual impairment in Germany: a slight fall in prevalence
    Robert P Finger
    Department of Ophthalmology, University of Bonn, Geramny
    Dtsch Arztebl Int 109:484-9. 2012
  4. ncbi Prevalence and causes of registered blindness in the largest federal state of Germany
    Robert P Finger
    Department of Ophthalmology, University of Bonn, Ernst Abbe Str 2, 53127 Bonn, Germany
    Br J Ophthalmol 95:1061-7. 2011
  5. ncbi [Basic principles, planning and implementation of non-commercial clinical trials]
    R P Finger
    Universitäts Augenklinik Bonn, Ernst Abbe Str 2, 53127 Bonn
    Ophthalmologe 108:25-32. 2011
  6. ncbi [Understanding and preventing blindness]
    R Finger
    , Ernst-Abbe-Strasse 2, 53127, Bonn
    Ophthalmologe 104:838. 2007
  7. ncbi [Patient reported outcomes. Relevance and application in ophthalmology]
    R P Finger
    Universitäts Augenklinik Bonn, Ernst Abbe Strasse 2, 53127, Bonn, Deutschland
    Ophthalmologe 105:722-6. 2008
  8. ncbi [Access to healthcare services for elderly patients with neovascular age-related macular degeneration]
    R P Finger
    Universitätsaugenklinik Bonn, Ernst Abbe Str 2, 53127, Bonn, Deutschland
    Ophthalmologe 109:474-8. 2012
  9. ncbi Eighteen-month follow-up of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia
    P Charbel Issa
    Department of Ophthalmology, University of Bonn, Ernst Abbe Str 2, D 53127 Bonn, Germany
    Br J Ophthalmol 92:941-5. 2008
  10. ncbi [Methods for estimating personal costs of disease using retinal diseases as an example]
    G Porz
    Universitäts Augenklinik Bonn, Deutschland
    Ophthalmologe 107:216-20, 222. 2010

Collaborators

Detail Information

Publications12

  1. ncbi [Blindness in Germany: dimensions and perspectives]
    R P Finger
    Universitätsaugenklinik Bonn, Ernst Abbe Strasse 2, 53127, Bonn
    Ophthalmologe 104:839-44. 2007
    ..Healthcare policy makers need to consider this when discussing future planning and resource allocation. Preventive and rehabilitative services should be given a much higher priority...
  2. ncbi [Trends in inpatient treatment in ophthalmology in Germany]
    R P Finger
    Universitätsaugenklinik Bonn, Ernst Abbe Str 2, 53127, Bonn, Deutschland
    Ophthalmologe 110:224-9. 2013
    ..Over the last decade inpatient treatment has been reduced in favor of outpatient care or markedly shortened inpatient stays in most organ-specific surgical specialties such as ophthalmology in Germany...
  3. ncbi Blindness and visual impairment in Germany: a slight fall in prevalence
    Robert P Finger
    Department of Ophthalmology, University of Bonn, Geramny
    Dtsch Arztebl Int 109:484-9. 2012
    ..As the population at large is aging, the prevalence of blindness and visual impairment would be expected to rise. To assess this, we studied prevalence trends in Germany over the past three decades...
  4. ncbi Prevalence and causes of registered blindness in the largest federal state of Germany
    Robert P Finger
    Department of Ophthalmology, University of Bonn, Ernst Abbe Str 2, 53127 Bonn, Germany
    Br J Ophthalmol 95:1061-7. 2011
    ..5 million people in the federal state of Northrhine) assessing eligibility for an allowance payable to blind people was used to investigate the prevalence and the specific causes of blindness and visual impairment...
  5. ncbi [Basic principles, planning and implementation of non-commercial clinical trials]
    R P Finger
    Universitäts Augenklinik Bonn, Ernst Abbe Str 2, 53127 Bonn
    Ophthalmologe 108:25-32. 2011
    ....
  6. ncbi [Understanding and preventing blindness]
    R Finger
    , Ernst-Abbe-Strasse 2, 53127, Bonn
    Ophthalmologe 104:838. 2007
  7. ncbi [Patient reported outcomes. Relevance and application in ophthalmology]
    R P Finger
    Universitäts Augenklinik Bonn, Ernst Abbe Strasse 2, 53127, Bonn, Deutschland
    Ophthalmologe 105:722-6. 2008
    ..However, there are a number of advantages, such as improved interaction between physicians and patients and shared decision making, that may result in increased compliance...
  8. ncbi [Access to healthcare services for elderly patients with neovascular age-related macular degeneration]
    R P Finger
    Universitätsaugenklinik Bonn, Ernst Abbe Str 2, 53127, Bonn, Deutschland
    Ophthalmologe 109:474-8. 2012
    ..The current level and the estimated need of service provision for nv-AMD were assessed...
  9. ncbi Eighteen-month follow-up of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia
    P Charbel Issa
    Department of Ophthalmology, University of Bonn, Ernst Abbe Str 2, D 53127 Bonn, Germany
    Br J Ophthalmol 92:941-5. 2008
    ..To evaluate the effects of intravitreal bevacizumab for non-proliferative type 2 idiopathic macular telangiectasia (type 2 IMT) within a mean follow-up period of 18 months...
  10. ncbi [Methods for estimating personal costs of disease using retinal diseases as an example]
    G Porz
    Universitäts Augenklinik Bonn, Deutschland
    Ophthalmologe 107:216-20, 222. 2010
    ..Against this background a quantification of personal cost and vision-related quality of life was performed...
  11. ncbi Discrete arcs of increased fundus autofluorescence in retinal dystrophies and functional correlate on microperimetry
    M Fleckenstein
    Department of Ophthalmology, University of Bonn, Bonn, Germany
    Eye (Lond) 23:567-75. 2009
    ..To describe the occurrence of discrete arcs of increased fundus autofluorescence (FAF) associated with various retinal dystrophies and to assess their functional significance by fundus-controlled microperimetry...
  12. ncbi Intravitreal bevacizumab for choroidal neovascularisation associated with pseudoxanthoma elasticum
    R P Finger
    Department of Ophthalmology, University of Bonn, Ernst Abbe Str 2, 53127 Bonn, Germany
    Br J Ophthalmol 92:483-7. 2008
    ..To investigate the efficacy of intravitreal bevacizumab injections for treating choroidal neovascularisation (CNV) secondary to pseudoxanthoma elasticum (PXE)...